TENX | Tenax Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.68 - 4.93
52 Week Range	2.7700 - 33.44
Beta	N/A
Implied Volatility	277.16%
IV Rank	N/A
Day's Volume	55,723
Average Volume	52,809
Shares Outstanding	3,408,910
Market Cap	16,771,837
Sector	Healthcare
Industry	Biotechnology
IPO Date	1994-04-04

Valuation
Profitability
Growth
Health
P/E Ratio	-0.38
Forward P/E Ratio	N/A
EPS	-13.05
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5
Country	USA
Website	TENX

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

TENX's peers: CLRB, RGLS, ALLR, NRBO, HILS, VRAX, QNRX, BWV, PXMD, REVB, ZVSA, SONN, NAVB, CYTO, WINT, DRMA, ENSC, PBLA, BXRX, ADTX, UNCY

*Chart delayed

Analyzing fundamentals for TENX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TENX Fundamentals page.

Watching at TENX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on TENX Technicals page.